# TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes

> **NCT05462457** · — · RECRUITING · sponsor: **Kliniken Essen-Mitte** · enrollment: 150 (estimated)

## Conditions studied

- Breast Cancer
- Node-positive Breast Cancer

## Interventions

- **PROCEDURE:** Targeted axilllary dissection (TAD) followed by axillary lymph node dissection (ALND)

## Key facts

- **NCT ID:** NCT05462457
- **Lead sponsor:** Kliniken Essen-Mitte
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-07
- **Primary completion:** 2027-03
- **Final completion:** 2032-03
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05462457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05462457, "TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05462457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*